RecruitingNCT05275075
Identify microRNAs in Cachexia in Pancreatic Carcinoma
Pilot Trial to Identify microRNAs in Cachexia in Patients With Pancreatic Carcinoma
Sponsor
University of Oklahoma
Enrollment
100 participants
Start Date
Dec 7, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to determine the proportion of pancreatic patients who experience weight loss and cachexia, and to identify any differences in the genes between patient groups.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Male or female patient, who is ≥ 18 years old at the time of informed consent.
- Patients with operable pancreatic tumors diagnosed in the last 12 months prior to consent with clinical discretion or pathology confirmed as adenocarcinoma.
- Patient has stage I or higher disease who is considered a candidate for surgical resection of pancreatic cancer, with or without neoadjuvant chemotherapy.
- Ability to provide written informed consent and HIPAA authorization.
Exclusion Criteria2
- Patients with pancreatic adenocarcinoma who do not meet the criteria for surgical resection.
- Patient has cancer diagnosis other than primary pancreatic adenocarcinoma.
Interventions
OTHERPancreatic cancer microRNA and messenger RNA expression.
Tumor specimens from pancreatic patients will be analyzed for markers associated with muscle loss.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05275075
Related Trials
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
NCT04858334454 locations
Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)
NCT063845604 locations
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
NCT064233261 location
A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer
NCT070800212 locations
Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1
NCT066494741 location